Passage Bio (Nasdaq:PASG) - Cours de l'action, nouvelles et analyse

PASG Aperçu des actions

Passage Bio, Inc. est une société de médicaments génétiques qui développe des thérapies géniques pour les maladies du système nerveux central. Plus de détails

PASG analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

N'a pas de capitalisation boursière significative ( $30M )

+ 1 plus de risques

Passage Bio, Inc. Concurrents

Lumos Pharma

NasdaqGM:LUMO

US$37.4m

NextCure

NasdaqGS:NXTC

US$36.6m

Lantern Pharma

NasdaqCM:LTRN

US$33.2m

HOOKIPA Pharma

NasdaqCM:HOOK

US$33.6m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Passage Bio
Historique des cours de bourse
Prix actuel de l'action	US$0.48
Plus haut sur 52 semaines	US$1.79
Plus bas sur 52 semaines	US$0.45
Bêta	1.2
1Variation sur 1 mois	-18.10%
Variation sur 3 mois	-33.06%
Variation sur 1 an	-21.37%
3Variation sur 3 ans	-93.49%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-97.83%

Nouvelles et mises à jour récentes

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Sep 24

Recent updates

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Rendement pour les actionnaires

	PASG	US Biotechs	US Marché
7D	-17.2%	-7.5%	-1.2%
1Y	-21.4%	14.1%	30.4%

Rendement vs Industrie: PASG a sous-performé le secteur US Biotechs qui a rapporté 14.1 % au cours de l'année écoulée.

Rendement vs marché: PASG a sous-performé le marché US qui a rapporté 30.4 % au cours de l'année écoulée.

Volatilité des prix

Is PASG's price volatile compared to industry and market?
PASG volatility
PASG Average Weekly Movement	12.5%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de PASG a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de PASG ( 13% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2017	58	Will Chou	www.passagebio.com

Passage Bio, Inc. est une société de médicaments génétiques qui développe des thérapies géniques pour les maladies du système nerveux central. Elle développe PBGM01, un gène GLB1 fonctionnel codant pour la ß-galactosidase pour le GM1 infantile ; PBFT02, une granuline (GRN) fonctionnelle et un gène codant pour la progranuline (PGRN) pour le traitement de la DFT causée par une déficience en progranuline ; et PBKR03, un gène GALC fonctionnel codant pour l'enzyme hydrolytique galactosylceramidase pour la maladie de Krabbe infantile. La société développe le PBML04 pour le traitement de la leucodystrophie métachromatique, le PBAL05 pour le traitement de la sclérose latérale amyotrophique et d'autres programmes pour la maladie de Huntington.

Passage Bio, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Passage Bio se comparent-ils à sa capitalisation boursière ?
PASG statistiques fondamentales
Capitalisation boursière	US$29.77m
Bénéfices(TTM)	-US$68.80m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.4x

Ratio P/E

Le site PASG est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
PASG compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$68.80m
Les revenus	-US$68.80m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.11
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de PASG?

Voir les performances historiques et les comparaisons

PASG Aperçu des actions

Analyse des risques

Passage Bio, Inc. Concurrents

NasdaqGM:LUMO

US$37.4m

NasdaqGS:NXTC

US$36.6m

NasdaqCM:LTRN

US$33.2m

NasdaqCM:HOOK

US$33.6m

Historique des prix et performances

Nouvelles et mises à jour récentes

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Recent updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia